Speech by the Minister of Health, Labour and Welfare, Japan Yasuhisa Shiozaki at the US-ROK-Japan Trilateral Meeting on Vice President Biden's Cancer Moonshot Initiative
September 19, 2016
Lotte New York Palace Hotel
New York, the United States of America
Honorable Secretary Burwell, Minister Chung, distinguished delegates, ladies and
gentlemen. It is my great pleasure to be here at the Trilateral Meeting on Vice
President Biden's Cancer Moonshot Initiative on our common fight against cancer.
In Japan, currently about one-third of deaths are caused by cancer. However, this is
not mere vital statistics; behind solemn numbers, there lie countless pains and
sufferings, endured not only by patients themselves, but also by families and friends losing their loved ones. We must listen to their silent voices of agony and earnest wishes to survive, and summon our unbeatable courage and determination to
overcome cancer.
Ladies and gentlemen,
Our three countries have many common features in the state of cancer but with some
differences.
Lung cancer is the leading cause of cancer death in all three countries, whereas
breast cancer is more prevalent in the United States, and gastric and liver cancers are more so in Korea and Japan.
United States is well-known for its innovative capacity for health care R&D and
ingenious activities of health care entrepreneurs, giving rise to recent numerous
inventive cancer treatments.
Korea has a single health insurance and payment review system thoroughly
connected and analyzed by a computer network, which enable complete enumeration
of certain cancer directory.
We, Japan, have fairly smooth access to care throughout the country without large
degree of differences of care level to be delivered, leading to cancer detection at
2 significantly earlier stages. Cancer screening with endoscopy is another strength
that contributes to early detection particularly of gastric cancer. We also have a
substantial number of seeds in basic cancer research which can lead to the recent
example of an immune check-point inhibitor.
Therefore, I strongly believe that joint initiatives by three countries with many common features, bringing together our unique contributions, would formulate the best mingled endeavor for the first time in cancer history.
Ladies and gentleman,
Mr. Biden's "Cancer Moonshot" initiative, which I highly respect, shed light upon many indispensable features in our fight against cancer.
In Japan, our cancer program consists of three cornerstones: preventing avoidable
deaths, promoting cancer research and therapeutics, and building a society that
enables people to live with cancer. However, what people really wish is to cure
cancer. We must develop innovative diagnostics and treatments that are accessible
at an affordable cost. We must also prioritize childhood cancers and rare cancers for which treatment options are very limited. To these ends, we need to work with
doctors, researchers, and patients including cancer survivors. It is a common
challenge to all of us.
Precision medicine and immuno-therapy bring about more effective care with less
debilitating adverse effects than conventional treatments. Their development requires the best and the brightest researchers from multi-disciplinary sectors including medicine, bio-science, physics, radiology and computer science, all working together. Numerous Japanese research institutions launched initiatives to engage research institutions, academia and industry, which our Ministry strongly supports. In order to find the right treatment for the right patient at the right time, we need to accumulate integrated and carefully analyzed proteogenomic and clinical data. This endeavor can be drastically expedited by fully utilizing artificial intelligence and sharing data across borders. Our government will drastically enhance this strategy jointly with the Japan Agency for Medical Research and Development, or AMED, and the Japanese National Cancer Center, or NCC, in the coming years.
Ladies and gentlemen,
We, the Japanese Government, will fully support the "Cancer Moonshot" initiative.
And I am totally convinced that the United States, Korea and Japan constitute a
strong partnership under our common vision to fight against cancer.
3 Cancer patients can no longer wait. With a shared sense of utmost urgency, Japan
is fully committed to go hand-in-hand with the United States and Korea to accelerate
the way toward overcoming cancer.
Thank you.
gentlemen. It is my great pleasure to be here at the Trilateral Meeting on Vice
President Biden's Cancer Moonshot Initiative on our common fight against cancer.
In Japan, currently about one-third of deaths are caused by cancer. However, this is
not mere vital statistics; behind solemn numbers, there lie countless pains and
sufferings, endured not only by patients themselves, but also by families and friends losing their loved ones. We must listen to their silent voices of agony and earnest wishes to survive, and summon our unbeatable courage and determination to
overcome cancer.
Ladies and gentlemen,
Our three countries have many common features in the state of cancer but with some
differences.
Lung cancer is the leading cause of cancer death in all three countries, whereas
breast cancer is more prevalent in the United States, and gastric and liver cancers are more so in Korea and Japan.
United States is well-known for its innovative capacity for health care R&D and
ingenious activities of health care entrepreneurs, giving rise to recent numerous
inventive cancer treatments.
Korea has a single health insurance and payment review system thoroughly
connected and analyzed by a computer network, which enable complete enumeration
of certain cancer directory.
We, Japan, have fairly smooth access to care throughout the country without large
degree of differences of care level to be delivered, leading to cancer detection at
2 significantly earlier stages. Cancer screening with endoscopy is another strength
that contributes to early detection particularly of gastric cancer. We also have a
substantial number of seeds in basic cancer research which can lead to the recent
example of an immune check-point inhibitor.
Therefore, I strongly believe that joint initiatives by three countries with many common features, bringing together our unique contributions, would formulate the best mingled endeavor for the first time in cancer history.
Ladies and gentleman,
Mr. Biden's "Cancer Moonshot" initiative, which I highly respect, shed light upon many indispensable features in our fight against cancer.
In Japan, our cancer program consists of three cornerstones: preventing avoidable
deaths, promoting cancer research and therapeutics, and building a society that
enables people to live with cancer. However, what people really wish is to cure
cancer. We must develop innovative diagnostics and treatments that are accessible
at an affordable cost. We must also prioritize childhood cancers and rare cancers for which treatment options are very limited. To these ends, we need to work with
doctors, researchers, and patients including cancer survivors. It is a common
challenge to all of us.
Precision medicine and immuno-therapy bring about more effective care with less
debilitating adverse effects than conventional treatments. Their development requires the best and the brightest researchers from multi-disciplinary sectors including medicine, bio-science, physics, radiology and computer science, all working together. Numerous Japanese research institutions launched initiatives to engage research institutions, academia and industry, which our Ministry strongly supports. In order to find the right treatment for the right patient at the right time, we need to accumulate integrated and carefully analyzed proteogenomic and clinical data. This endeavor can be drastically expedited by fully utilizing artificial intelligence and sharing data across borders. Our government will drastically enhance this strategy jointly with the Japan Agency for Medical Research and Development, or AMED, and the Japanese National Cancer Center, or NCC, in the coming years.
Ladies and gentlemen,
We, the Japanese Government, will fully support the "Cancer Moonshot" initiative.
And I am totally convinced that the United States, Korea and Japan constitute a
strong partnership under our common vision to fight against cancer.
3 Cancer patients can no longer wait. With a shared sense of utmost urgency, Japan
is fully committed to go hand-in-hand with the United States and Korea to accelerate
the way toward overcoming cancer.
Thank you.
-
ASEAN-Japan Health Ministers' Meeting: Universal Health Coverage (UHC) and Population Ageing Roundtable Discussion 1 (UHC)
- Speech by Yasuhisa Shiozaki, the Minister of Health, Labour and Welfare, Japan
July 15, 2017
Tokyo, Japan
-
ASEAN-Japan Health Ministers' Meeting: Universal Health Coverage (UHC) and Population Ageing Opening remarks
- Speech by Yasuhisa Shiozaki, the Minister of Health, Labour and Welfare, Japan
July 15, 2017
Tokyo, Japan
-
U.S.-Japan Dialogue: Strengthening the Partnership on Global Health at CSIS
- Special Remarks
by Yasuhisa Shiozaki, the Minister of Health, Labour and Welfare, Japan
May 3, 2017
Washington, D.C.
-
OECD Health Ministerial Ministerial Break-out Session: Adapting Health Systems to New Technologies Theme 1: Tackling High-cost Treatments and Personalised Medicine
- Speech by Yasuhisa Shiozaki, the Minister of Health, Labour and Welfare, Japan
January 17, 2017
-
OECD Health Ministerial Session 1: Releasing Health System Resources for Better Value Care: Tackling Ineffective Health Spending and Waste
- Speech by Yasuhisa Shiozaki, the Minister of Health, Labour and Welfare, Japan
January 17, 2017